
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy Inc. is noted for its robust growth trajectory, particularly within its industrial injury prevention segment, which has displayed strong momentum in recent quarters. The company anticipates an adjusted EBITDA for FY/25 to be in the range of $93 million to $97 million, reflecting an approximate 8.6% increase compared to the previous year. Additionally, projected revenue increases from both its primary segment and the growing industrial injury prevention business suggest a strong outlook, with expectations of 17.1% and 10% growth for different portions of the business relative to prior periods.
Bears say
US Physical Therapy Inc. has encountered ongoing pricing challenges within its Medicare segment, which have negatively impacted revenue growth. With 2026 being the first year free from these pricing pressures, the company may still face difficulties in adjusting and optimizing operations to recover fully from the preceding pandemic conditions. Moreover, dependence on various payment sources, including managed care and Medicaid, poses a risk due to potential reimbursement rate fluctuations that could further strain financial performance.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares